ARCA biopharma, Inc.Company Review & Valuation

ABIO
Nasdaq
Latest Price
3.90USD
Market Capitalization
17.48mUSD

About ARCA biopharma, Inc.

ARCA biopharma, Inc., a biopharmaceutical company, focuses on developing genetically-targeted therapies for cardiovascular diseases. The company's lead product candidate is Gencaro, a pharmacologically beta-blocker and mild vasodilator, which is in clinical trial for the treatment of atrial fibrillaShow more tion in chronic heart failure patients with reduced left ventricular ejection fraction. It also engages in the development of a preclinical plan for AB171, a new chemical entity for the treatment of various cardiovascular indications, such as peripheral arterial disease and chronic heart failure. The company has a collaboration agreement with Medtronic, Inc. for the support of GENETIC-AF Phase 2B clinical trials; and Laboratory Corporation of America to provide the companion diagnostic test and services to support GENETIC-AF trial. ARCA biopharma, Inc. is headquartered in Westminster, Colorado. Show less

Industry
Biotechnology
HQ Location
Westminster, Colorado

Stock Price

Price data not available for ARCA biopharma, Inc..

Performance

Please login or create a free account to view the contents of this section.

Similar Companies

back to top